A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
- Status
- COMPLETED
- Phase
- N/A
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
INCB047986 in Rheumatoid Arthritis
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study of Ruxolitinib in Colorectal Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Ruxolitinib in Pancreatic Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE3
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
- Status
- TERMINATED
- Phase
- PHASE3
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2